CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis

Inclusion Criteria: * Male and female patients aged 12 - 70 years. * Who was diagnosed with Atopic Dermatitis according to Haniffin and Rajka criteria. * Whose affected TBSA is over 5% and below 30%, and IGA score is 2 (mild) to 3 (moderate). * Who voluntarily agreed to participate in the study and signed an informed consent form. Exclusion Criteria: * Who has skin diseases other than atopic dermatitis or scar in the affected area which can affect the study, determined by the study investigators. * Who has clinically significant medical history or diseases involving liver, kidney, neurological system, psychical disorder that can affect study results. * Who has used systemic steroids, antibiotics, immunosuppressants, or received phototherapy within 28 days before study drug administration. * Who has used topical steroids, topical calcineurin inhibitors or antibiotics to treat atopic dermatitis within 14 days before study drug administration. * Who has used or is expected to inevitably use prohibited concomitant medications during the study. * Women who is pregnant /breast-feeding, or who has childbearing potential and does not use available contraceptives. * Who has dosed other study medications within 30 days before screening. * Who is determined ineligible for study participation by investigators for any other reasons.